New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
14:03 EDTBGMDBG Medicine price target lowered to $7 from $16.50 at Ladenburg
Ladenburg reduced its target on BG Medicine after the company announced that it would transition to a marketing-oriented business model and hire a sales team to sell CardioSCORE. The firm thinks the move will provide the company with greater control over CardioSCOPE, but that the move creates more balance sheet risk and may necessitate the introduction of additional partners. The firm reiterates a Buy rating.
News For BGMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
08:45 EDTBGMDBG Medicine sees requiring additional capital in 'near future'
Paul Sohmer, CEO of BG Medicine, said: "FDA clearance of the first automated assay for galectin-3 represents a significant commercial milestone for BG Medicine. Our commercial strategy will increasingly rely on the success of our automated partners to commercialize automated testing for galectin-3. We anticipate that beginning in the second half of 2015 our growth in revenues will depend on the timing and extent to which our automated partners are successful in gaining adoption of their automated tests for galectin-3. Concurrently, we will continue to manage aggressively our operating expenses and cash burn. We also expect that we will require additional capital in the near future to continue our operations and grow our business."
07:18 EDTBGMDBG Medicine files Premarket Notification with FDA for BGM Galectin-3 Test
Subscribe for More Information
07:11 EDTBGMDBG Medicine reports Q4 EPS (4c), one estimate (5c)
Reports Q4 revenue $554,000, one estimate $800,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use